|Articles|March 1, 2002
Neurotech wins license to develop Amgen's CNTF
Paris - Neurotech S.A. will exclusively develop and market Amgen Inc.'s ciliary neurotrophic factor (CNTF), a protein that has protective effects in animals with retinitis pigmentosa.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
























